The Baker lab at the University of Washington harnessed AI to design highly specific protein binders for diverse peptide–MHC complexes, enhancing personalized immunotherapy targeting. Detailed in a Science publication, these low-immunogenicity proteins recognize viral and tumor antigens including the challenging PRAME target. This work builds on Nobel-winning advances in de novo protein design, rapidly generating candidates for scalable cell-based therapies against cancer and infectious diseases.